BioSpace News Archive

POSIMIR ® (bupivacaine solution) for infiltration use reduced mean pain over 72 hours after arthroscopic subacromial decompression surgery compared with vehicle control and improved several measures of postoperative opioid use.

KBI Biopharma SA and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland.

Oncocyte Corporation today announced that DetermaIO™, the Company’s proprietary test designed to determine the likelihood of benefit of immune checkpoint inhibitors (ICIs), was featured in a podium presentation at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022, held in Barcelona, Spain from 29 June-2 July, 2022.

Protega Pharmaceuticals LLC (Protega) today announced the commercial launch of RoxyBond™ (oxycodone) immediate-release (IR) tablets in the United States. RoxyBond™ was approved by the U.S. Food and Drug Administration (FDA) as an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled “Development of an Immunohistochemical Assay for Siglec-15” in Laboratory Investigation.

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that its management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2022.

Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize programmable medicines with its commensal virome platform, today announced a pre-print publication in bioRxiv featuring the first anellovirus structure identified from a synthetically produced human anellovirus capsid protein.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the Second quarter of 2022 after market close on Tuesday, August 9, 2022.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the MARKET combination trial for AMT-101 in biologic-naïve patients with moderate-to-severe UC.

ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Company leadership will participate in two upcoming investor conferences in July.